fda approved semaglutide compound Novo asks to prevent compounders from making GLP-1 knockoffs FDA Warns About Compounded Versions

The development of multiagonists, including GLP-1glucagon and GIPGLP-1glucagon receptor agonists, especially with the potential for glucagon receptor activation, marks a significant advancement in the field

In a report published in November, 2023, based on data collected between 2015 and 2022, an estimated 30% of Canadian adults were classified as obese based on BMI measures (i.e., BMI greater than 30)

Food and Drug Administration prescribing label and safety guidance (official FDA source)

History of Type 2 Diabetes or Obesity You may also be eligible for GLP-1 treatment if you have a medical history of type 2 diabetes, heart disease, or both

Still, limited lifestyle support, no app, and unresponsive customer service kept me from rating it higher